{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:41:39Z","timestamp":1787611299860,"version":"build-2736575974"},"reference-count":47,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.<\/ns4:p>","DOI":"10.12688\/f1000research.17295.1","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T05:10:10Z","timestamp":1552626610000},"page":"293","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Bronchiectasis insanity: Doing the same thing over and over again and expecting different results?"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1968-1400","authenticated-orcid":false,"given":"Mark","family":"Metersky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"377-84","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013.","volume":"14","author":"D Weycker","year":"2017","journal-title":"Chron Respir Dis."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"432-9","DOI":"10.1378\/chest.11-2209","article-title":"Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.","volume":"142","author":"A Seitz","year":"2012","journal-title":"Chest."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"186-93","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.","volume":"47","author":"J Quint","year":"2016","journal-title":"Eur Respir J."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"10-3","DOI":"10.1183\/13993003.01567-2015","article-title":"Bronchiectasis: how to be an orphan with many parents?","volume":"47","author":"P Goeminne","year":"2016","journal-title":"Eur Respir J."},{"key":"ref-5","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00081-2015","article-title":"The EMBARC European Bronchiectasis Registry: protocol for an international observational study.","volume":"2","author":"J Chalmers","year":"2016","journal-title":"ERJ Open Res."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"982-92","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.","volume":"151","author":"T Aksamit","year":"2017","journal-title":"Chest."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"738-49","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.","volume":"2","author":"A Barker","year":"2014","journal-title":"Lancet Respir Med."},{"key":"ref-8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.","volume":"51","author":"A De Soyza","year":"2018","journal-title":"Eur Respir J."},{"key":"ref-9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.","volume":"51","author":"T Aksamit","year":"2018","journal-title":"Eur Respir J."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1073-9","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.","volume":"69","author":"D Bilton","year":"2014","journal-title":"Thorax."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"975-82","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.","volume":"189","author":"C Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02444-2017","article-title":"RESPIRE: breathing new life into bronchiectasis.","volume":"51","author":"S Chotirmall","year":"2018","journal-title":"Eur Respir J."},{"key":"ref-13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00763-2017","article-title":"Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis.","volume":"50","author":"P Burgel","year":"2017","journal-title":"Eur Respir J."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"117-27","DOI":"10.1016\/j.jaci.2017.04.022","article-title":"Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease.","volume":"141","author":"A Dicker","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"e28526","DOI":"10.1371\/journal.pone.0028526","article-title":"Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy.","volume":"6","author":"V Papayannopoulos","year":"2011","journal-title":"PLoS One."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"1329-34","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.","volume":"113","author":"A O'Donnell","year":"1998","journal-title":"Chest."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"661-7","DOI":"10.1016\/j.rmed.2011.12.021","article-title":"The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis.","volume":"106","author":"C Nicolson","year":"2012","journal-title":"Respir Med."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"1843-8","DOI":"10.1164\/ajrccm.159.6.9809074","article-title":"Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis.","volume":"159","author":"E Daviskas","year":"1999","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"423-4","DOI":"10.1016\/S0140-6736(70)90042-5","article-title":"Sputum viscosity in cystic fibrosis.","volume":"296","author":"L Reid","year":"1970","journal-title":"Lancet."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"715-26","DOI":"10.1016\/S2213-2600(18)30053-5","article-title":"Bronchiectasis: new therapies and new perspectives.","volume":"6","author":"J Chalmers","year":"2018","journal-title":"Lancet Respir Med."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"413-7","DOI":"10.1164\/ajrccm.154.2.8756815","article-title":"Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.","volume":"154","author":"P Wills","year":"1996","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis.","volume":"50","author":"E Polverino","year":"2017","journal-title":"Eur Respir J."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1120-7","DOI":"10.1016\/j.chest.2017.04.167","article-title":"Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.","volume":"152","author":"E Henkle","year":"2017","journal-title":"Chest."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"23-30","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.","volume":"340","author":"B Ramsey","year":"1999","journal-title":"N Engl J Med."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"CD012733","DOI":"10.1002\/14651858.CD012733.pub2","article-title":"Continuous versus intermittent antibiotics for bronchiectasis.","volume":"6","author":"T Donovan","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"809-15","DOI":"10.1016\/j.jcf.2016.05.001","article-title":"Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.","volume":"15","author":"P Flume","year":"2016","journal-title":"J Cyst Fibros."},{"key":"ref-27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.","volume":"49","author":"A Hill","year":"2017","journal-title":"Eur Respir J."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1410-20","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \"Frequent Exacerbator Phenotype\" in Bronchiectasis.","volume":"197","author":"J Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"632-47","DOI":"10.1183\/13993003.01888-2015","article-title":"Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration.","volume":"48","author":"S Aliberti","year":"2016","journal-title":"Eur Respir J."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1110-8","DOI":"10.1136\/thoraxjnl-2016-208481","article-title":"Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts.","volume":"71","author":"M McDonnell","year":"2016","journal-title":"Thorax."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"51-8","DOI":"10.1016\/j.rmed.2016.01.016","article-title":"The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study.","volume":"112","author":"J Chalmers","year":"2016","journal-title":"Respir Med."},{"key":"ref-32","article-title":"Assessment of INS1007 in Subjects with non-cystic fibrosis bronchiectasis"},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1384-93","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.","volume":"195","author":"J Chalmers","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"880-90","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.","volume":"392","author":"P Flume","year":"2018","journal-title":"Lancet."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1251-9","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.","volume":"309","author":"J Altenburg","year":"2013","journal-title":"JAMA."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"660-7","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.","volume":"380","author":"C Wong","year":"2012","journal-title":"Lancet."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"1260-7","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.","volume":"309","author":"D Serisier","year":"2013","journal-title":"JAMA."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1583-9","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial.","volume":"380","author":"N Ryan","year":"2012","journal-title":"Lancet."},{"key":"ref-39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01532-2016","article-title":"The development and validation of the Bronchiectasis Health Questionnaire.","volume":"49","author":"A Spinou","year":"2017","journal-title":"Eur Respir J."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"575-85","DOI":"10.1007\/s00408-017-0038-x","article-title":"The Objective Assessment of Cough Frequency in Bronchiectasis.","volume":"195","author":"A Spinou","year":"2017","journal-title":"Lung."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"576-85","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. An international derivation and validation study.","volume":"189","author":"J Chalmers","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"524-33","DOI":"10.1016\/j.rmed.2012.12.009","article-title":"Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.","volume":"107","author":"R Stockley","year":"2013","journal-title":"Respir Med."},{"key":"ref-43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2016.PA4088","article-title":"Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis.","volume":"48","author":"H Watz","year":"2016","journal-title":"Eur Respir J."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"281-6","DOI":"10.1016\/j.cyto.2017.08.005","article-title":"The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis.","volume":"99","author":"S Tsikrika","year":"2017","journal-title":"Cytokine."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"657-65","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.","volume":"186","author":"J Chalmers","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-46","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00451-2017","article-title":"Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD.","volume":"50","author":"M Contoli","year":"2017","journal-title":"Eur Respir J."},{"key":"ref-47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01269-2018","article-title":"Treatable traits in bronchiectasis.","volume":"52","author":"R Boaventura","year":"2018","journal-title":"Eur Respir J."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-293\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-293\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-293\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T13:46:12Z","timestamp":1553867172000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-293\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":47,"URL":"https:\/\/doi.org\/10.12688\/f1000research.17295.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.18908.r45752","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18908.r45751","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-293\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.18908.r45751, Surinder S Birring, Division of Asthma, Allergy and Lung Biology, Faculty of Life Sciences and Medicine, King's College London, London, UK, 15 Mar 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-293\/v1#referee-response-45751","order":0,"name":"referee-response-45751","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18908.r45752, Sophie Gohy, Pneumology department and CF reference center, Cliniques universitaires Saint-Luc, Brussels, Belgium, 15 Mar 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-293\/v1#referee-response-45752","order":1,"name":"referee-response-45752","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}